Talk:Treprostinil
Latest comment: 8 years ago by Rod57 in topic We should mention its significant cost
| This is the talk page for discussing improvements to the Treprostinil article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
| |||||||||||||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Treprostinil.
|
Structure is incorrect
editAll stereocenters in this structure appear to be inverted relative to what the name suggests--ChemSpiderMan (talk) 05:32, 29 May 2008 (UTC)
- Apparently, the PubChem record I used as a source was faulty. I've uploaded a new version in prostaglandin orientation with the correct stereochemistry. Fvasconcellos (t·c) 14:11, 29 May 2008 (UTC)
We should mention its significant cost
edit[http://www.medpagetoday.com/Cardiology/Hypertension/55533?xid=nl_mpt_cardioreport_2016-01-06 Projected Uptravi Cost: $160-170K a Year But new PAH drug is still cheaper than some alternatives] implies Tyvaso costs over $160,000 per annum - Should surely be alluded to somehow (with a better source) ? doi:10.1185/030079905X75104. PMID 16368052. (in further reading) may be such but I dont have full access. - Rod57 (talk) 03:44, 7 January 2016 (UTC)